focus -WSS

focus

author：focus 2025-09-30 16:25:59 - browse：243

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： First U.S. drug developed to treat liver disease MASH is approved

focus

WSS

The story of mRNA: From a loose idea to a tool that may help curb Covid

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Why we need to separate burnout from moral injury in health care

Gene therapy has helped boys walk. Can scientists keep it that way?

RaDonda Vaught links Vanderbilt hospital issues to patient death

#NeedHerScience: shining a light on gender disparities in medicine

entertainment

focus

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Boston's new lab space is opening empty

Moonlake's readout produced a cash windfall. Risks remain

Colonoscopy at 40? Study finds a possible benefit

Malaria cases in Florida and Texas: Here’s what you need to know

Do masks work? RCTs can't tell us

Medicare details structure of new drug price negotiation program

Disclosing genetic information: not as worrisome as once feared

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ask STAT: What do you want to know about ChatGPT in medicine?

Wikipedia

John Green on his newest strategy for fighting tuberculosis

How to save health care price transparency rules

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Do masks work? RCTs can't tell us

What would happen to your eyes if you looked at the solar eclipse?

Why depression after traumatic brain injury is distinct

hotspot

hotspot

focus

leisure time